Nonprofit Civica goes after insulin prices in a big way, prepping for $30 vials by 2024
As millions of insulin-dependent Americans have seen their out-of-pocket costs soar over the last few years, the market controlled by the three big insulin manufacturers — Sanofi, Eli Lilly and Novo Nordisk — is ripe for disruption.
And that’s just what nonprofit generic drugmaker Civica is looking to do, with plans to manufacture and market three of the most common forms of insulin: glargine, lispro and aspart. Perhaps most importantly, the company says it plans to set the price of each insulin to the consumer at no more than $30 per vial and no more than $55 for a box of five pen cartridges.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
